New Test Refines Melanoma Risk, Ushering in Personalized Care Era

DENVER, CO – March 27, 2026 – The landscape of melanoma care is shifting towards a more personalized future, as new data reveals how a specialized diagnostic test can look beyond traditional staging methods to provide a more accurate picture of a patient's true risk. At the 2026 American Academy of Dermatology (AAD) Annual Meeting, Castle Biosciences presented compelling findings showing its DecisionDx-Melanoma test can significantly refine mortality risk predictions for patients with cutaneous melanoma, potentially transforming how treatment plans are developed.

The study, involving nearly 1,900 patients, demonstrates that the gene expression profile (GEP) test can identify individuals whose risk of death from melanoma is substantially higher or lower than their formal stage would suggest. This allows clinicians to move beyond a one-size-fits-all approach and tailor surveillance and treatment intensity to the unique biological signature of a patient's tumor.

Beyond Traditional Staging

For decades, the American Joint Committee on Cancer (AJCC) staging system has been the gold standard for classifying melanoma. This system relies on physical characteristics of the tumor—such as its thickness, whether the skin above it is broken (ulceration), and if it has spread to lymph nodes or other parts of thebody. While indispensable for providing a general prognosis and guiding initial treatment, this clinicopathologic approach has limitations. It can group together tumors that look similar under a microscope but behave very differently from a biological standpoint.

This is where gene expression profiling comes in. Instead of only looking at the tumor's physical traits, tests like DecisionDx-Melanoma analyze the activity of specific genes within the tumor cells. This molecular-level analysis provides a direct window into the tumor's underlying biology and its potential for aggressive behavior. By examining a 31-gene signature, the test classifies tumors into low-risk (Class 1A) and high-risk (Class 2B) categories, offering a layer of prognostic information that complements, rather than replaces, the foundational AJCC stage.

"The findings being presented at AAD reinforce that staging alone does not tell the whole story," said Dr. Harrison Nguyen, the study's lead author and a double board-certified dermatologist, in a statement released by the company. "Incorporating DecisionDx-Melanoma into routine risk assessment provides physicians with biologic information that complements staging and supports more personalized management decisions."

The Evidence from AAD 2026

The new data presented in Denver adds significant weight to the case for integrating GEP testing into standard care. The study leveraged the national Surveillance, Epidemiology, and End Results (SEER) Program registries, linking clinical test data from 1,868 patients with stage I-III melanoma to long-term survival outcomes.

The results were striking. The test effectively stratified patients within the same AJCC stage into vastly different risk groups. For instance, among patients with thin T1 tumors—often considered lower risk—the five-year melanoma-specific survival rate was 96.7% for those with a low-risk (Class 1A) test result. However, for T1 patients with a high-risk (Class 2B) result, the survival rate plummeted to 70.0%, a risk profile more aligned with thicker, more advanced melanomas.

A similar, and even more dramatic, disparity was seen in patients with more advanced Stage IIB–III disease. Those with a low-risk gene signature had an 87.4% five-year survival rate, suggesting their prognosis was much better than their stage would imply. In stark contrast, patients in the same stages but with a high-risk result faced a grim 48.5% five-year survival rate.

These findings highlight the test's ability to re-categorize risk in a clinically meaningful way. It can identify patients who might be over-treated based on staging alone, as well as those whose aggressive tumors might otherwise be missed, allowing for earlier and more intensive intervention.

Clinical Impact and Patient Empowerment

The practical implications of this refined risk assessment are profound, impacting decisions across the entire spectrum of melanoma management. One of the most immediate applications is in guiding the decision to perform a sentinel lymph node biopsy (SLNB). This surgical procedure, used to check if melanoma has spread to nearby lymph nodes, carries its own risks and is not always necessary, particularly for thin melanomas. The test can provide crucial data to help doctors and patients weigh the benefits against the risks more accurately.

For patients identified as high-risk by the test, clinicians may opt for more frequent follow-ups, more intensive imaging schedules to screen for metastasis, and earlier consideration of powerful adjuvant therapies. Conversely, a patient with a high AJCC stage but a low-risk gene profile might be a candidate for less intensive surveillance, sparing them the cost, radiation exposure, and anxiety of frequent scans.

This shift toward "risk-aligned management" also empowers patients. Armed with a more precise understanding of their personal prognosis, individuals can engage in more meaningful, shared decision-making with their healthcare team. For some, a low-risk result can provide immense relief and reduce the psychological burden of a cancer diagnosis. For others, a high-risk result, while difficult, provides the clarity needed to commit to a more aggressive but potentially life-saving treatment path.

"It changes the conversation," noted one independent oncologist not involved with the study. "When you can show a patient objective, biological data about their specific tumor, it moves the discussion from general statistics to their personal situation. It allows us to justify why we are recommending more surveillance for one patient and less for another, even if their stage on paper is the same."

Navigating the Healthcare Landscape

The integration of advanced diagnostics into clinical practice is not without its hurdles, which often include questions of market adoption, competition, and accessibility. With over 220,000 tests ordered since its launch, DecisionDx-Melanoma has already achieved significant penetration, suggesting clinicians see value in the information it provides. This adoption is bolstered by a growing library of over 50 peer-reviewed publications validating its performance.

The test exists within a dynamic field of oncology diagnostics that includes other molecular tests, artificial intelligence-driven image analysis, and liquid biopsies that detect circulating tumor DNA. However, its strong evidence base and focus on early-stage cutaneous melanoma have carved out a significant niche.

Crucially, accessibility has been a key focus. The test has secured Medicare coverage, a critical milestone that often paves the way for broader coverage by private insurance companies. This helps ensure that a patient's access to this prognostic information is not solely dependent on their ability to pay out-of-pocket. As the body of evidence continues to grow, as highlighted by the latest AAD presentation, the case for its routine use becomes stronger, further pushing personalized medicine to the forefront of cancer care.